Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a biotechnology company focused on the research and development of immuno-oncology therapies. Its pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein in Phase IIa trials for EBV+ non-Hodgkin lymphoma, acral/mucosal melanoma, relapsed/refractory melanoma post-PD-1 therapy, and biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein in Phase Ia for solid tumors; HX301, an oral multi-kinase inhibitor in Phase IIa for glioblastoma; and HX111, an ADC drug candidate for solid tumors. The company also develops proprietary platforms such as VersatiBody, a multifunctional antibody discovery platform that generated two clinical-stage first-in-class bifunctional fusion proteins (HX009 and HX044), and has completed preclinical development of multiple ADC and bispecific molecules, including HX111 (OX40-ADC) and HX116 (PD-L1×VEGF BsAb-ADC). Additionally, its autoRx40 autoimmune therapeutic platform has completed the design of multiple candidate molecules for autoimmune diseases, such as HX035, HX038, and HX138. Incorporated in 2014, the company is headquartered in Wuhan, China.